vs

Side-by-side financial comparison of HomeTrust Bancshares, Inc. (HTB) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

HomeTrust Bancshares, Inc. is the larger business by last-quarter revenue ($53.6M vs $35.5M, roughly 1.5× RECURSION PHARMACEUTICALS, INC.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 3.7%). HomeTrust Bancshares, Inc. produced more free cash flow last quarter ($45.3M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 3.5%).

HomeTrust Bancshares Inc. is an Asheville, North Carolina–based bank holding company with $4.3 billion in assets and 33 branches in North and South Carolina, Georgia and Tennessee. It is the parent of seven community banks—HomeTrust Bank, Tryon Federal Bank, Shelby Savings Bank, Home Savings Bank, Industrial Federal Bank, Cherryville Federal Bank and Rutherford County Bank.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

HTB vs RXRX — Head-to-Head

Bigger by revenue
HTB
HTB
1.5× larger
HTB
$53.6M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+678.1% gap
RXRX
681.7%
3.7%
HTB
More free cash flow
HTB
HTB
$92.6M more FCF
HTB
$45.3M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
3.5%
HTB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HTB
HTB
RXRX
RXRX
Revenue
$53.6M
$35.5M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
37.0%
-304.8%
Net Margin
-304.2%
Revenue YoY
3.7%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$0.93
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HTB
HTB
RXRX
RXRX
Q4 25
$53.6M
$35.5M
Q3 25
$54.1M
$5.2M
Q2 25
$54.4M
$19.2M
Q1 25
$50.9M
$14.7M
Q4 24
$51.7M
$4.5M
Q3 24
$50.6M
$26.1M
Q2 24
$50.6M
$14.4M
Q1 24
$50.0M
$13.8M
Net Profit
HTB
HTB
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$16.5M
$-162.3M
Q2 25
$17.2M
$-171.9M
Q1 25
$14.5M
$-202.5M
Q4 24
$-178.9M
Q3 24
$13.1M
$-95.8M
Q2 24
$12.4M
$-97.5M
Q1 24
$15.1M
$-91.4M
Gross Margin
HTB
HTB
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
HTB
HTB
RXRX
RXRX
Q4 25
37.0%
-304.8%
Q3 25
38.5%
-3327.6%
Q2 25
40.1%
-916.8%
Q1 25
36.2%
-1297.9%
Q4 24
35.4%
-4042.4%
Q3 24
33.2%
-377.1%
Q2 24
31.3%
-697.4%
Q1 24
38.0%
-698.4%
Net Margin
HTB
HTB
RXRX
RXRX
Q4 25
-304.2%
Q3 25
30.5%
-3135.3%
Q2 25
31.6%
-894.2%
Q1 25
28.5%
-1373.3%
Q4 24
-3935.5%
Q3 24
25.9%
-367.5%
Q2 24
24.6%
-676.6%
Q1 24
30.1%
-662.4%
EPS (diluted)
HTB
HTB
RXRX
RXRX
Q4 25
$0.93
$-0.17
Q3 25
$0.95
$-0.36
Q2 25
$1.00
$-0.41
Q1 25
$0.84
$-0.50
Q4 24
$0.83
$-0.56
Q3 24
$0.76
$-0.34
Q2 24
$0.73
$-0.40
Q1 24
$0.88
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HTB
HTB
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$324.7M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$600.7M
$1.1B
Total Assets
$4.5B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HTB
HTB
RXRX
RXRX
Q4 25
$324.7M
$743.3M
Q3 25
$315.8M
$659.8M
Q2 25
$297.2M
$525.1M
Q1 25
$299.8M
$500.5M
Q4 24
$279.2M
$594.4M
Q3 24
$293.5M
$427.6M
Q2 24
$294.2M
$474.3M
Q1 24
$380.5M
$296.3M
Total Debt
HTB
HTB
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
HTB
HTB
RXRX
RXRX
Q4 25
$600.7M
$1.1B
Q3 25
$595.8M
$1.0B
Q2 25
$579.3M
$919.1M
Q1 25
$565.4M
$933.9M
Q4 24
$551.8M
$1.0B
Q3 24
$540.0M
$524.6M
Q2 24
$523.6M
$584.4M
Q1 24
$513.2M
$401.2M
Total Assets
HTB
HTB
RXRX
RXRX
Q4 25
$4.5B
$1.5B
Q3 25
$4.6B
$1.4B
Q2 25
$4.6B
$1.3B
Q1 25
$4.6B
$1.3B
Q4 24
$4.6B
$1.4B
Q3 24
$4.6B
$726.5M
Q2 24
$4.7B
$775.9M
Q1 24
$4.7B
$557.8M
Debt / Equity
HTB
HTB
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HTB
HTB
RXRX
RXRX
Operating Cash FlowLast quarter
$49.5M
$-46.1M
Free Cash FlowOCF − Capex
$45.3M
$-47.3M
FCF MarginFCF / Revenue
84.5%
-133.1%
Capex IntensityCapex / Revenue
7.8%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$93.8M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HTB
HTB
RXRX
RXRX
Q4 25
$49.5M
$-46.1M
Q3 25
$-11.3M
$-117.4M
Q2 25
$-8.8M
$-76.4M
Q1 25
$71.7M
$-132.0M
Q4 24
$45.4M
$-115.4M
Q3 24
$43.8M
$-59.2M
Q2 24
$5.9M
$-82.2M
Q1 24
$-9.0M
$-102.3M
Free Cash Flow
HTB
HTB
RXRX
RXRX
Q4 25
$45.3M
$-47.3M
Q3 25
$-12.0M
$-117.6M
Q2 25
$-10.2M
$-79.6M
Q1 25
$70.7M
$-133.8M
Q4 24
$42.4M
$-116.7M
Q3 24
$43.1M
$-63.8M
Q2 24
$5.7M
$-83.4M
Q1 24
$-9.6M
$-109.0M
FCF Margin
HTB
HTB
RXRX
RXRX
Q4 25
84.5%
-133.1%
Q3 25
-22.2%
-2272.5%
Q2 25
-18.7%
-413.9%
Q1 25
138.7%
-907.4%
Q4 24
82.0%
-2567.7%
Q3 24
85.1%
-244.6%
Q2 24
11.2%
-578.5%
Q1 24
-19.2%
-789.9%
Capex Intensity
HTB
HTB
RXRX
RXRX
Q4 25
7.8%
3.5%
Q3 25
1.4%
4.7%
Q2 25
2.5%
16.4%
Q1 25
2.0%
12.4%
Q4 24
5.9%
28.6%
Q3 24
1.3%
17.5%
Q2 24
0.5%
8.2%
Q1 24
1.1%
48.2%
Cash Conversion
HTB
HTB
RXRX
RXRX
Q4 25
Q3 25
-0.68×
Q2 25
-0.51×
Q1 25
4.93×
Q4 24
Q3 24
3.34×
Q2 24
0.48×
Q1 24
-0.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons